Efficacy and Safety of Endothelin A Receptor Antagonists in IgA Nephropathy

Tian Z, Yang Y, Mei J, et al.

This systematic review and meta-analysis was designed to evaluate the safety and efficacy of endothelin A receptor antagonists in patients with IgA nephropathy. Endothelin A receptor antagonists can significantly reduce urine protein-creatinine ratio, lower systolic and diastolic blood pressure, and delay eGFR decline; however, they may cause acute kidney injury, anemia, cough, dizziness, fluid retention, and hypotension.